Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06229899 |
| Other study ID # |
Metabolic health-Follistatin |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 15, 2022 |
| Est. completion date |
January 15, 2023 |
Study information
| Verified date |
January 2024 |
| Source |
Goztepe Prof Dr Suleyman Yalcin City Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
There is no clear boundary on which obese individuals should be considered metabolically
healthy and which should be considered metabolically unhealthy. It is also not very clear
whether the individuals who are considered metabolically healthy will remain healthy in the
future. The objective of this study was to assess potential disparities in serum follistatin
levels between these two distinct groups. Furthermore, the study sought to investigate
whether this disparity could serve as a reliable indicator for distinguishing between
metabolically healthy and unhealthy obese individuals.
Description:
Individuals with similar body mass indexes may have different metabolic health and
cardiovascular risks. Research shows that some individuals with comparable body mass index
(BMI) are metabolically healthy and have a lower risk of cardiovascular issues, while others
are metabolically unhealthy and have a higher risk. Studies indicate that the lifestyles of
metabolically healthy and unhealthy obese individuals, such as diet, physical activity, and
sleep patterns, do not differ significantly, even though the individuals have similar levels
of total or subcutaneous adiposity. However, it has been shown that metabolically healthy
obese individuals tend to have lower levels of visceral adiposity compared to unhealthy ones.
Patients with BMI≥30, who applied to the internal medicine clinic, were included in the
study. Among these patients, those without criteria of metabolic syndrome other than an
increase in waist circumference (blood pressure ≥130/85 mmHg, fasting blood sugar ≥100 mg/dl,
triglycerides ≥150 mg/dl, HDL-cholesterol <40 mg/dl in men and <50 mg/dl in women) and
without prediabetes were defined as metabolically healthy obese individuals. Those with at
least 1 metabolic syndrome criterion other than an increase in waist circumference were
classified as metabolically unhealthy obese individuals. The participants' fasting blood
sugar levels, HbA1c levels, insulin levels, lipid panel results, liver enzymes levels,urea
levels, creatinine levels, whole blood count, and thyroid hormones were examined.
Anthropometric measurements including height,weight and waist circumference were also taken
for each individual.
Participants were then invited back to repeat follistatin levels.
